Answers are grounded in this paper and cite their sources.
The antirhinovirus agent chalcone Ro 09-0410 was tested in double-blind place-controlled volunteer trials for its protective efficacy against experimental rhinovirus infection. Fifty volunteers received either drug (26 volunteers) or placebo (24 volunteers) both before and after challenge with 20-40 tissue culture infecting dose (TCID50) of human rhinovirus 2 (RV2). There was no evidence that medication significantly reduced the incidence of infection or illness, indeed there was some increase in the nasal secretion produced.
No takes yet. Share an insight, caveat, or question.
Al‐Nakib et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: